Understand the source comparison
Peptides for Erectile Dysfunction Research: Mechanism Comparison
Peptide research for erectile dysfunction spans multiple biological systems. No single compound addresses all dysfunction subtypes. The table below compares primary mechanisms, documented efficacy signals from published trials, and research application context
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptide research for erectile dysfunction spans multiple biological systems. No single compound addresses all dysfunction subtypes. The table below compares primary mechanisms, documented efficacy signals from published trials, and research application contexts for the most investigated peptide classes.
- Melanocortin Agonists (PT-141)
- MC4R activation in hypothalamus; central dopaminergic erectile initiation independent of NO
- Phase III trials: IIEF improvement 6.2 points vs 1.8 placebo (p<0.001) in psychogenic dysfunction
- Neurogenic dysfunction models; PDE5-refractory populations; central vs peripheral pathway comparison
- Most clinically advanced non-NO pathway; subcutaneous bioavailability and 2.7-hour half-life suit on-demand research protocols
- Kisspeptin Analogues (Kisspeptin-10)
- GPR54 receptor activation on GnRH neurons; restoration of LH/FSH pulsatility and endogenous testosterone production
- RCT data: LH increased 4.1× baseline, testosterone +6.5 nmol/L at 24 hours, IIEF +6.3 points vs +1.1 placebo at 4 weeks
- Hypogonadotropic hypogonadism; metabolic syndrome with HPG axis suppression; obesity-related sexual dysfunction
- Addresses upstream hormonal dysfunction PDE5 inhibitors cannot; requires GnRH pathway integrity to function
- VIP + Phentolamine
- VPAC receptor activation; cAMP-mediated smooth muscle relaxation; alpha-adrenergic blockade removes sympathetic tone
- Diabetic cohort: 72% rigid erection response with VIP/phentolamine vs 31% sildenafil monotherapy
- NO pathway impairment models; diabetic autonomic neuropathy; intracavernosal delivery pharmacodynamics
- Mechanistically sound but limited by 2-minute half-life; combination protocol required for consistent response
- GLP-1 Receptor Agonists (off-label investigation)
- Endothelial NO synthase upregulation; reduction of oxidative stress; improvement in HbA1c and insulin sensitivity
- Observational data: IIEF scores improved in 48% of diabetic men on semaglutide for glycemic control (mechanism unclear if direct or secondary to metabolic improvement)
- Metabolic syndrome; type 2 diabetes with vascular dysfunction; endothelial repair pathway investigation
- Indirect mechanism. Endothelial function improvement secondary to glycemic control and weight reduction; not specific to erectile pathways